首页> 外文期刊>Drug Safety - Case Reports >Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy
【24h】

Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy

机译:术后出血在给予接受抗逆转录病毒治疗的患者的单剂量rivaroxaban后

获取原文
       

摘要

A 62-year-old man was admitted to hospital for elective revision of a left total hip arthroplasty. His history was significant for human immunodeficiency virus (HIV) infection for which he was taking the following antiretroviral agents (ARVs): etravirine, ritonavir, darunavir, raltegravir and tenofovir/emtricitabine. Rivaroxaban 10?mg daily was commenced on the second postoperative day for venous thromboembolism (VTE) prophylaxis. Approximately 24?h later, the patient developed hypotension and anaemia, accompanied by thigh swelling due to bleeding at the surgical site. Fluid resuscitation was commenced with red cell transfusion. The prothrombin time (PT) was prolonged at 24.3 (10.6–15.3)?s, and a rivaroxaban level taken 24?h after administration was 75?ng/mL. Rivaroxaban was ceased, the PT normalised within 24?h of stopping the drug, and the patient made an uneventful recovery. None of the other coadministered drugs are known to interact with rivaroxaban, or are likely to, based on their metabolic pathways. Rivaroxaban, a substrate for cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), is contraindicated in patients concomitantly treated with strong inhibitors of both these systems, e.g. protease inhibitors (PIs) such as ritonavir (based on in vitro data and a pharmacokinetic study in healthy volunteers). No published data are available on the PI darunavir, a moderate inhibitor; however, concomitant use with rivaroxaban should also be avoided. A prolonged PT and a rivaroxaban trough level greater than eight times that predicted from pharmacokinetic modelling suggests that bleeding was due to increased exposure to rivaroxaban, probably due to an interaction with ritonavir and darunavir. This is supported by a Drug Interaction Probability Scale (DIPS) score of 8. An interaction between a single dose of rivaroxaban and ARVs may be clinically significant; therefore, the patient’s medication history should be extensively evaluated to identify any potential interactions.
机译:一名62岁的男子被录取为医院接受左侧髋关节置换术的选修版本。他的历史对人类免疫缺陷病毒(HIV)感染具有重要意义,他服用以下抗逆转录病毒剂(ARV):etravirine,Ritonavir,Darunavir,Raltegravir和Tenofovir / Emtricitabine。 Rivaroxaban 10?MG日常在静脉血栓栓塞(VTE)预防的第二次术后日开始。以后大约24?H,患者开发了低血压和贫血,伴随着外科部位出血的大腿肿胀。红细胞输血开始流体复苏。凝血酶原时间(Pt)在24.3(10.6-15.3)℃下延长,并且在给药后24μl的蓖麻水平为75μg/ ml。 Rivaroxaban被停止,Pt标准化在24℃,患者恢复不变。众所周知,没有其他共胆药物与rivaroxaban相互作用,或者可能基于其代谢途径。 Rivaroxaban,用于细胞色素P450(CYP)3A4和P-糖蛋白(P-GP)的底物,在伴随着这些系统的强抑制剂的患者中禁用,例如,彼此禁止。蛋白酶抑制剂(PIS)如Ritonavir(基于体外数据和健康志愿者的药代动力学研究)。 Pi Darunavir没有出版的数据,适度抑制剂;然而,也应该避免与Rivaroxaban的伴随使用。延长的Pt和蓖麻油矛盾水平超过药代动力学建模预测的八倍,表明出血是由于暴露于罗冈班班,这可能是由于与Ritonavir和Darunavir的互动。这是由药物相互作用概率刻度(倾枝)得分的支持8.单剂量的rivaroxaban和ARV之间的相互作用可能是临床显着的;因此,应广泛评估患者的药物历史以确定任何潜在的相互作用。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号